No annual revenue total was found in Cellectar Biosciences, Inc.'s SEC filings.
Cellectar Biosciences, Inc. (CLRB) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$23.1 million. As of Jun 30, 2026 it held $34.0 million in cash and investments and $1.5 million in total debt.
Revenue
—
Net income (TTM)
$-22.32M
+23.2% vs year-ago TTM
Operating cash flow (TTM)
$-19.47M
+43.7% vs year-ago TTM
Free cash flow (TTM)
$-19.51M
EPS (TTM)
$-3.77
+80.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
4.24M
+0.0% vs prior year
Net cash
$32.46M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLRB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Florham Park, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1279704
- Former names
- NOVELOS THERAPEUTICS, INC. (until Feb 11, 2014); COMMON HORIZONS INC (until Jun 2, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$23.0M | -$51.8M | -$39.0M | -$28.8M | -$24.1M |
| Net income | -$21.8M | -$44.6M | -$42.8M | -$31.8M | -$24.1M |
| Diluted EPS | -$8.35 | -$41.89 | -$3.50 | -$4.51 | -$4.35 |
| Operating cash flow | -$23.1M | -$47.6M | -$32.4M | -$25.2M | -$22.6M |
| Free cash flow | -$23.1M | -$47.7M | -$33.2M | -$25.4M | -$22.7M |
| Total assets | $15.0M | $25.5M | $12.1M | $21.6M | $37.2M |
| Total liabilities | $5.1M | $9.8M | $25.9M | $12.1M | $4.2M |
| Stockholders' equity | $8.5M | $14.3M | -$15.2M | $8.2M | $29.1M |
| Cash and investments | $13.2M | $23.3M | $9.6M | $19.9M | $35.8M |
| Total debt | $410,000 | $494,000 | $553,000 | $604,000 | $302,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jul 10, 2026 | Jul 7, 2026 |
| 8-K |
Current report
Officer or director change
|
May 18, 2026 | May 17, 2026 |
| 8-K |
Current report
Results of operations
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 1000 Cellectar Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.